{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rheumatoid-arthritis/diagnosis/when-to-suspect-ra/","result":{"pageContext":{"chapter":{"id":"b9d257ab-0ebb-52bf-908a-8ebebe6c550c","slug":"when-to-suspect-ra","fullItemName":"When to suspect RA","depth":2,"htmlHeader":"<!-- begin field c8be1f75-8c53-4d69-b700-eee4e4e44e23 --><h2>When should I suspect rheumatoid arthritis?</h2><!-- end field c8be1f75-8c53-4d69-b700-eee4e4e44e23 -->","summary":"","htmlStringContent":"<!-- begin item 705603b9-a87c-4c5a-9562-47a38ec13ac7 --><!-- begin field 03cf3846-a508-48b7-8a2c-b145f36eec38 --><ul><li><strong>Suspect rheumatoid arthritis (RA) in anyone with persistent synovitis, where no <a class=\"topic-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/diagnosis/differential-diagnosis/\">other underlying cause</a> is obvious </strong>(for example, psoriatic arthritis). <ul><li>Clinical judgement should be used to decide if the synovitis is 'persistent' (lasting a few weeks rather than days).</li></ul></li><li><strong>RA typically causes symmetrical synovitis of the small joints of the hands and feet, although <em>any </em>synovial joint may be affected. </strong>Clinical features of synovitis include:<ul><li><strong>Pain, swelling, heat and stiffness in affected joints.</strong><ul><li>Pain — usually this is worse at rest or during periods of inactivity.</li><li>Swelling — around the joint (not bone swelling) giving a 'boggy' feel on palpation. </li><li>Stiffness — early morning stiffness usually last over 1 hour (a history of prolonged morning stiffness is more helpful when forming a diagnosis than currently having morning stiffness for early RA).</li></ul></li></ul></li><li><strong>Persistent synovitis, and a poorer prognosis, is more likely when:</strong><ul><li>A greater number of joints are affected (the more joints the worse the prognosis). </li><li>There is swelling and tenderness in the affected joints (particularly small joints). </li><li>The proximal interphalangeal joints and metacarpophalangeal joints are affected and there is symmetry of joints affected. </li><li>There is a positive metacarpophalangeal squeeze test – pain on squeezing the metacarpophalangeal or metatarsophalangeal joints together.</li></ul></li><li>An inability to make a fist or flex fingers is associated with an ability to diagnose RA from other diagnoses.</li><li><strong>In addition to joint synovitis, RA may present with:</strong><ul><li>Rheumatoid nodules — hard, firm swellings over extensor surfaces occur in a third of people with RA. </li><li>Extra-articular features such as vasculitis, or involvement of other body systems (for example, eye, lungs, and heart).</li><li>Systemic features of malaise, fatigue, fever, sweats, and weight loss. </li><li>A family history of RA. </li></ul></li><li><strong>The presentation of RA is variable. </strong>Most people have an insidious onset, but others can have a rapid, or relapsing and remitting course (such as a palindromic presentation). </li></ul><!-- end field 03cf3846-a508-48b7-8a2c-b145f36eec38 --><!-- end item 705603b9-a87c-4c5a-9562-47a38ec13ac7 -->","topic":{"id":"80425c66-11ed-5a54-aecf-455f339cb0cd","topicId":"d9596563-d663-48ca-8d6a-4ddeb263b46e","topicName":"Rheumatoid arthritis","slug":"rheumatoid-arthritis","lastRevised":"Last revised in April 2020","chapters":[{"id":"e5b4cb7c-c830-59e0-a369-a8151bd28e7c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28d53d37-f5b2-5ab0-bd6f-6c6858fc63e4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8eb76d85-83a8-5bb1-be89-15a9e86def8d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7eba8b39-2fb0-52b0-8988-5d108c1720fa","slug":"changes","fullItemName":"Changes"},{"id":"add57644-4b68-5377-b8ce-b0cc395570f0","slug":"update","fullItemName":"Update"}]},{"id":"62d68b4b-4522-5afb-88fe-48b87fc31a2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f9fe7005-bf48-5a4e-bc7c-08550e792a18","slug":"goals","fullItemName":"Goals"},{"id":"cc0b2b43-25e2-5936-ad94-217419fd0126","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6a0fead6-ca32-5399-9b1b-22b31fc0c765","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f76001a5-99f4-5086-bc05-c1cd7535aab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fb29501f-d465-5652-b659-ffb4e5c8e928","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3181265d-dee9-5587-974d-b4bae95c10ee","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"167941e5-411a-5afd-94af-8e7725b24b1a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bb48f4e9-23c4-5828-bccb-666f4dbc512d","slug":"definition","fullItemName":"Definition"},{"id":"06cc7595-3f6c-59d6-929b-964159afde4d","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"8fb1fc93-039a-5d6b-a86d-aeb61578f11d","slug":"complications","fullItemName":"Complications"}]},{"id":"e352008d-7a0c-55ba-b778-c6218ef4ef69","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b9d257ab-0ebb-52bf-908a-8ebebe6c550c","slug":"when-to-suspect-ra","fullItemName":"When to suspect RA"},{"id":"25d80dc3-ea8a-5560-8a0b-3a64b87c5690","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5de822df-3081-5ed6-a21b-e3e2925436bd","slug":"investigations-for-suspected-ra","fullItemName":"Investigations for suspected RA"}]},{"id":"6f1e7941-f462-5d64-8822-8328310b81b9","fullItemName":"Management","slug":"management","subChapters":[{"id":"2ed609a5-1052-56f5-b263-63d4e5325949","slug":"suspected-ra","fullItemName":"Scenario: Suspected RA"},{"id":"0ba5ec6e-3f0f-5157-8e24-55ef24b2cfe9","slug":"confirmed-ra","fullItemName":"Scenario: Confirmed RA"},{"id":"c490cb4d-f228-5c81-b9f2-0ac419b6d60a","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"13cb1ed1-b962-5e8a-88c8-8b7185af06df","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e875cc8d-258b-5535-9d34-40f03cb150c7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b45cf27-1cfb-591d-a936-5e49910f88ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"93bd3cb0-31a7-5acf-bc5f-8858b54e466b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a24a6436-a685-5277-8c22-524ebe895154","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4258a438-16bd-591d-bd95-5d6a682e1696","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"58298e48-e237-5259-b79b-da11e96f0a4e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6c1abdea-39c1-5537-8e4f-6e6ff3a71736","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e352008d-7a0c-55ba-b778-c6218ef4ef69","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"8e03d244-86e8-5327-ae43-d8ab83883e98","slug":"basis-for-recommendation-976","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 1d231ecd-220e-41d8-b806-48003619b579 --><h3>Basis for recommendation</h3><!-- end field 1d231ecd-220e-41d8-b806-48003619b579 -->","summary":null,"htmlStringContent":"<!-- begin item 97659c2e-cbf8-45a8-a6f2-2c50ee95855b --><!-- begin field 62e0acc6-8aad-4a31-be9d-bae4674508ac --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Rheumatoid arthritis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">NICE, 2018a</a>], <em>Rheumatoid arthritis: national clinical guideline for management and treatment in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">National Collaborating Centre for Chronic Conditions, 2018</a>], the British Medical Journal (BMJ) best practice guide <em>Rheumatoid Arthritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">BMJ, 2018</a>], and expert opinion in a narrative review <em>Rheumatoid Arthritis: Common Questions About Diagnosis and Management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">Wasserman, 2018</a>]. </p><ul><li>NICE recommends that a diagnosis of rheumatoid arthritis (RA) should be suspected in anyone with persistent synovitis. However, NICE does define 'persistent' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">NICE, 2018a</a>].  <ul><li>CKS recommends using clinical judgement to determine whether synovitis is persistent or not.</li></ul></li><li>NICE advises that the main priority for non-specialists is to recognise synovitis as soon as possible, which means there should be a low threshold for detecting heat, swelling, pain, loss of function, morning stiffness, and systemic features of inflammation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">National Collaborating Centre for Chronic Conditions, 2018</a>].  <ul><li>If some of these signs and symptoms are present in small joints, then the threshold for considering RA needs to be lowered considerably.</li><li>Some authorities have suggested if squeezing metacarpophalangeal or metatarsophalangeal joints is tender, this is sufficient to trigger concern.</li></ul></li><li>The American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) developed classification criteria for RA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">Aletaha et al, 2010</a>]. However, although the authors accept that there is potential to use the criteria for diagnosis, their aim was to improve classification for research purposes rather than provide diagnostic criteria or a referral guide for primary healthcare practitioners.<ul><li>NICE states that because an early persistent synovitis, where other pathologies have been ruled out, needs to treated as if it is RA to try to prevent damage to joints, identification of persistent synovitis and appropriate early management is more important than whether the disease satisfies classification criteria [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">National Collaborating Centre for Chronic Conditions, 2018</a>]. </li><li>Therefore CKS has not included the classification criteria in the recommendations.</li></ul></li></ul><!-- end field 62e0acc6-8aad-4a31-be9d-bae4674508ac --><!-- end item 97659c2e-cbf8-45a8-a6f2-2c50ee95855b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}